Skip to content

BridgeBio Pharma BBIO Total Operating Expenses

Discontinued — last reported Q1 '21

Total Operating Expenses at other companies

Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$445.22M+84.9%
Arrowhead Research logo
Arrowhead ResearchARWR
$215M+33.1%
Viatris logo
ViatrisVTRS
$1.24B-69.4%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$62.67M+20.7%

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$12.98B+119%
Enterprise value$15.36B+178%
P/S22.4×-24.1×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: BridgeBio Pharma’s 10-Q, filed May 6, 2021, on SEC EDGAR. View the filing →